# Pizarra — PT-pseudo_47d8b39fd07f (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_47d8b39fd07f
Task: 1

Encounter: Urology - outpatient on 22 Jan 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 60-year-old male
  - PSA: 21.0 ng/mL
  - mpMRI — PI-RADS score: 3 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.19 ng/mL²
  - PSA velocity: 5.99 ng/mL/yr
  - Prior PSA: 23.5 ng/mL
  - Prostate volume: 112.15 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.4009605 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, COPD
  - Problem list / PMHx: Hypertension, COPD
  - Current medication: amlodipine, valsartan, lisinopril, metoprolol, tiotropium, salbutamol PRN
  - Allergies: NKA
  - Additional notes: PSA 21 ng/mL. PI-RADS 3. PSAD 0.19. Prostate volume 112 mL. csPCa 0.40.

Vitals: weight 78 kg, height 186 cm, BMI 22.5, BP 140/82 mmHg, HR 74 bpm. Smoking: Non-smoker.

Chief complaint: Rising PSA trajectory combined with intermediate mpMRI findings warrants specialist review following a previously Negative biopsy.

History: The patient, a 60-year-old retired baker, initially presented for evaluation of PSA elevation in early 2022, with values climbing to 23.5 ng/mL before stabilizing at 21.0 ng/mL. He reports moderate lower urinary tract symptoms, chiefly nocturia and a weak stream, yielding an IPSS score of 17. A Non-smoker, his past medical history encompasses well-controlled hypertension and mild COPD, currently managed with amlodipine, valsartan, lisinopril, metoprolol, tiotropium, and salbutamol PRN. He maintains an active lifestyle, cycling to work five days weekly, and drinks roughly seven units of alcohol each week. Married, he resides in a multi-generational household with his wife and adult son, a setup he describes as highly supportive. Beyond urinary complaints, he notes stable right knee osteoarthritis that required six physiotherapy sessions last year, alongside occasional mild insomnia. He explicitly denies bone pain, haematuria, or unexplained weight loss. He has previously declined research study participation and wishes to maintain that position.

Physical examination: DRE: Normal exam. Prostate texture is symmetrically enlarged, smooth, and firm, lacking discrete nodules or asymmetry. General assessment remains unremarkable, recording blood pressure at 140/82 mmHg and heart rate at 74 bpm, with no peripheral lymphadenopathy or abdominal masses detected.

Patient info: retired baker; Married; Lives with adult child (multi-generational household).
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 7 units / week; exercise Cycling 5x/week (commuter); IPSS score: 17/35 (moderate LUTS).

Recent other appointments: GP practice nurse — flu vaccination; Physiotherapy — lower back, six sessions; Radiology — chest X-ray (routine).
Admin: Patient declined research participation previously; respect for AS-related trials.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.47 +/- 0.12   (95% CI 0.23-0.71)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.12  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 1.00 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'discuss': p +/- dp straddles 0.5. The classifier genuinely CANNOT tell the two answers apart here. Its number is a starting point only. Measured accuracy in this tier on the labelled cohort: 0.488 over 43 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior negative biopsy.

CRITERION VERDICT: DEFER BIOPSY.

The criterion: Re-biopsy (targeted) when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for a PI-RADS 3 or lower picture that has not changed.

In the labelled cohort this criterion matched the reading urologist in 16 of the 18 cases with a prior negative biopsy.

Track record of this criterion on the labelled cohort: 16 of 18 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI show a PI-RADS 4-5 lesion that warrants re-biopsy?
  - psa_trend (get_psa_trend) -> Does the PSA trend suggest a significant change or trajectory that contradicts the prior negative biopsy status?
  - previous_notes (get_previous_notes) -> What was the prior management context, including prior grade and surveillance pathway?

This case hinges on whether the mpMRI findings have changed since the prior negative biopsy, and what the established management context is, as the guideline suggests deferral for PI-RADS 3 or lower without change.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the context that the PI-RADS 3 finding is in the context of a rising PSA velocity (5.99 ng/mL/yr) and a prior negative biopsy.
The prior did not weigh the specific PSA density (0.19 ng/mL²) or the specific PI-RADS 3 score against the guideline criterion for deferral.
The prior did not account for the specific track record of the guideline criterion (16/18 match) or the specific context of the prior negative biopsy status.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a probability of 0.47 +/- 0.12, placing it in the 'discuss' tier. This suggests the model cannot distinguish between biopsy and no biopsy. This is wrong because the guideline criterion explicitly states to defer biopsy for a PI-RADS 3 picture that has not changed, which the prior failed to apply. The prior did not account for the specific track record of this criterion, which is crucial for a definitive decision.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the mpMRI show a PI-RADS 4-5 lesion that warrants re-biopsy?
psa_trend - Does the PSA trend suggest a significant change or trajectory that contradicts the prior negative biopsy status?
previous_notes - What was the prior management context, including prior grade and surveillance pathway?
laboratory panel - What is the specific PSA density value and how does it relate to the guideline's PSA-D cut-off?
GUIDELINE ANCHOR - The guideline constrains the decision by stating to defer re-biopsy for a PI-RADS 3 picture that has not changed.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_47d8b39fd07f", "radiology_report": "Subject: mpMRI Prostate | LUMC | 15 Jan 2025\n\nClinical Indication:\nAssessment of PSA trend (23.5 ng/mL in Feb 2024, now 21.0 ng/mL) after a prior Negative systematic biopsy.\n\nFINDINGS:\nGland measures 112.15 mL. T2 sequences show a 12 mm focus in the right mid-gland peripheral zone, showing intermediate signal with subtly indistinct borders. DWI indicates moderate restriction alongside moderately lowered ADC values. DCE highlights focal early enhancement. Seminal vesicles appear normal. Pelvic lymph nodes show no suspicious features. Extracapsular extension is absent.\n\nIMPRESSION:\nPI-RADS 3 lesion in the right mid-gland peripheral zone. Prostate volume 112.15 mL. PSAD 0.19 ng/mL/mL. csPCa predicted probability 0.4009605."}
get_psa_trend
{"case_id": "PT-pseudo_47d8b39fd07f", "psa_trend": [{"date": "Mar 2022", "val": 2.5}, {"date": "Feb 2023", "val": 6.9}, {"date": "Feb 2024", "val": 19.3}, {"date": "Jan 2025", "val": 21.0}]}
get_previous_notes
{"case_id": "PT-pseudo_47d8b39fd07f", "previous_notes": [{"date": "01 Aug 2023", "author": "Dr. R. van den Berg (GP)", "text": "01 Aug 2023 - Dr. R. van den Berg (GP): Routine follow-up captured PSA at 11.5 ng/mL. Moderate lower urinary tract symptoms are present, though haematuria and bone pain are denied. Urology referral for further workup and multiparametric MRI was arranged with patient consent."}, {"date": "27 May 2024", "author": "Dr. R. van den Berg (GP)", "text": "27 May 2024 - Dr. R. van den Berg (GP): Repeat testing shows PSA elevation to 23.5 ng/mL. LUMC imaging identified a PI-RADS 3 lesion, while the earlier systematic biopsy yielded Negative results. Urology re-evaluation was scheduled to review the imaging and laboratory data."}]}
get_lab_results
{"case_id": "PT-pseudo_47d8b39fd07f", "laboratory_results": [{"name": "PSA", "val": "21.0 ng/mL", "date": "09 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "3.22 ng/mL", "date": "09 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "15%", "date": "09 Dec 2024", "flag": "L"}, {"name": "Haemoglobin", "val": "14.4 g/dL", "date": "09 Dec 2024", "flag": ""}, {"name": "WBC", "val": "5.7 x10^9/L", "date": "09 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "183 x10^9/L", "date": "09 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "88 umol/L", "date": "09 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "09 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "21.6 nmol/L", "date": "09 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "69 U/L", "date": "09 Dec 2024", "flag": ""}, {"name": "LDH", "val": "191 U/L", "date": "09 Dec 2024", "flag": ""}, {"name": "HbA1c", "val": "6.1 %", "date": "09 Dec 2024", "flag": ""}]}

NOT RETRIEVED
The family history of prostate cancer was not retrieved as it is not relevant to the biopsy decision per the retrieval economy rules.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- PSA velocity: 5.99 ng/mL/yr, indicating a rising trajectory.
- MRI finding: PI-RADS 3 lesion in the right mid-gland peripheral zone, which is equivocal.

AGAINST sampling this patient now:
- Guideline criterion: Defer biopsy for a PI-RADS 3 picture that has not changed.
- Prior status: Prior biopsy was Negative.

WHERE THIS LEANS
The evidence is split between the rising PSA velocity and the PI-RADS 3 finding, but the explicit guideline criterion strongly favors deferral when the finding has not changed.
LEAN: defer

[Opened in this round: radiology_report, psa_trend, previous_notes, laboratory_results. Open on the board so far: radiology_report, psa_trend, previous_notes, laboratory_results.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=no, protocol=no, evidence=no.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes', 'laboratory_results']; still missing nothing.

The retrieved evidence, particularly the explicit guideline criterion, strongly supports deferring the biopsy based on the PI-RADS 3 finding not having changed, despite the rising PSA velocity.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: NO BIOPSY   (confidence: clear)

I recommend deferring biopsy because the guideline criterion explicitly advises against repeating a negative biopsy for a PI-RADS 3 finding that has not changed. This decision is supported by the retrieved radiology report showing a PI-RADS 3 lesion, and the prior status of a Negative biopsy. Although the PSA velocity was rising (5.99 ng/mL/yr), the lack of change in the imaging finding is the decisive factor overriding the trajectory.

Variables that carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
